All In Biotech

Drug Trial Radar · NCT07932132

Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Aug 8, 2026

Primary completion

Jun 30, 2027

Study completion Jun 30, 2028

Sponsor

Sponsor type
Industry
Collaborators
Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, open-label, randomized controlled clinical trial designed to evaluate rabies virus neutralizing antibody responses to rabies vaccination among patients infected with human immunodeficiency virus (HIV). Eligible participants will be divided into two groups according to baseline CD4+ T cell count before randomization. Within each group, participants will be randomly assigned to one of two different rabies vaccination regimens for simulated post-exposure prophylaxis. Blood samples will be collected before vaccination and at scheduled time points after vaccination. Rabies virus neutralizing antibody titers will be tested to assess the seroconversion rate and geometric mean concentration (GMC). Adverse events after vaccination will also be recorded.

Conditions

  • Rabies
  • HIV Infections

Interventions

  • Rabies Vaccine (Vero Cell) for Human Use, Freeze-driedBiological

    0.5mL for each dose, manufactured by Liaoning Chengda Biotechnology CO., LTD, administered by intramuscular injection into the deltoid muscle of the lateral upper arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroconversion rate and geometric mean concentration (GMC) of rabies virus neutralizing antibodies at 14 days after completion of the full vaccination courseTime frame: 14 days after completion of the full vaccination course
  2. Incidence of adverse events after vaccinationTime frame: 30 minutes, 0-7 days, and 8-14 days after each vaccine dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Fourth People's Hospital of Nanning City

    Nanning, Guangxi, China · Recruiting

  • Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention

    Nanning, Guangxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.